Despite the arrival of high-throughput platforms, the new discoveries have barely challenged the use of imaging parameters to aid detection of abnormalities in the heart and biomarkers of heart failure (HF) and that of traditional biomarkers such as NT-proBNP and cardiac troponin-I/T to evaluate cardiac injury, and these two modalities firmly remain as the gold standard clinical practice for long-term prognostication. This evidence concerns the gene NPPB and hydrops fetalis.